Advertisement
Advertisement
U.S. Markets close in 5 hrs 28 mins
Advertisement
Advertisement
Advertisement
Advertisement

United Therapeutics Corporation (UTHR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
252.46-3.19 (-1.25%)
As of 10:30AM EST. Market open.
Advertisement

United Therapeutics Corporation

1040 Spring Street
Silver Spring, MD 20910
United States
301 608 9292
https://www.unither.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees965

Key Executives

NameTitlePayExercisedYear Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.Founder, Chairman & CEO3.51M5.08M1955
Mr. Michael I. BenkowitzPres & COO1.96M17.34M1972
Mr. James C. EdgemondCFO & Treasurer1.42MN/A1968
Mr. Paul A. Mahon J.D.Exec. VP, Gen. Counsel & Corp. Sec.1.67M12.39M1964
Mr. Dewey Steadman C.F.A.Head of Investor RelationsN/AN/AN/A
Ms. Holly HobsonAssociate VP of HRN/AN/AN/A
Kevin T. GraySr. VP of Strategic Operations & LogisticsN/AN/AN/A
Mr. Patrick PoissonExec. VP of Technical OperationsN/AN/A1968
Mr. Gil GoldenSr. VP & Chief Medical OfficerN/AN/AN/A
Dr. Leigh PetersonVP of Product Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of October 1, 2022 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder Rights: 3; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement